A Prospective, Randomized, Multi-Center, Subject- and Evaluator-Blinded, Parallel Comparison of Dysport, When Reconstituted at 1.5 mL and 2.5 mL, for the Treatment of Moderate to Severe Glabellar Lines
Phase of Trial: Phase IV
Latest Information Update: 30 Dec 2016
At a glance
- Drugs Botulinum toxin A (Primary)
- Indications Glabellar lines
- Focus Therapeutic Use
- Sponsors Galderma
- 24 Dec 2016 Status changed from active, no longer recruiting to completed.
- 15 Jul 2016 Planned End Date changed from 1 Aug 2016 to 1 Oct 2016.
- 15 Jul 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Oct 2016.